申请人:THE PROCTER & GAMBLE COMPANY
公开号:EP0863149A1
公开(公告)日:1998-09-09
The present invention relates to oligosaccharide-containing 14-aminosteroid compounds and the pharmaceutically-acceptable acid salts or esters thereof of the general formula:
wherein
a) R1 is
(i) COOR5, where
R5 is hydrogen, a 1-6 carbon lower alkyl ; a 1-6 carbon lower alkyl substituted by an amino group; an arylalkyl or heteroarylalkyl or a carbocyclic ring, or
(ii) CHR6OH, where
R6 is a hydrogen atom or 1-6 carbon lower alkyl group, or
(iii) COR''', where R''' is hydrogen; 1-6 carbon lower alkyl; 1-6 carbon lower alkyl substituted amino; amino or dialkylamino; and
b) R2 is -NR7R8, where
R7 and R8, which may be the same or different, are hydrogen atoms or a 1-6 carbon lower alkyl ; and
c) R3 is
(i) an oligosaccharide sugar residue having the following structure:
where R9 is hydrogen; methyl; hydroxy; carboxy; acetoxy; arylalkyloxy; heteroarylalkyloxy or benzoxy; R10 is hydrogen; methyl; carboxy; acetoxy; arylalkyloxy; heteroarylalkyloxy; benzoxy or hydroxy; R11 is oxygen; wherein further when R11 is a substituent on the terminal monosaccharide sugar residue; R11 is OH; methyl; acetoxy; arylalkyloxy; heteroarylalkyloxy; and R12 is a hydrogen; methyl; methylhydroxymethyl; or acetoxymethyl; or
(ii) an oligosaccharide sugar residue having the following structure:
where R14 and R15, which may be the same or different, are hydrogen; 1-6 carbon lower alkyl; heteroarylalkyl; arylalkyl; heteroaryl or aryl; R17 can be hydrogen; hydroxy; acetoxy or benzoxy; R18 and R19 are hydroxy; acetoxy and benzoxy; or
(iii) an oligosaccharide residue having the following structure:
where R14 and R15, which may be the same or different, are hydrogen; 1-6 carbon lower alkyl; heteroaryl alkyl; arylalkyl; heteroaryl or aryl; R14a is oxygen; wherein further when R14a is a substituent on the terminal monosaccharide sugar residue; R14a must be hydroxy; methyl; acetoxy; arylalkyloxy or heteroarylalkyloxy; and
d) R4 is
(i) OH, or
(ii) H, or
(iii) OR13, where R13 is a monosaccharide sugar residue; acetoxy; benzoxy; arylalkyl or heteroarylalkyl; and
e) Z is
(i) -CH-, where a and b are single bonds, or
(ii) =C, where either a or b is a double bond.
The present invention also relates to a process for introducing an amino group at the 14-position on a steroid nucleus wherein said amino group is diasteroselectively introduced onto the 14-position of the steroid nucleus via an iodoisocyanate addition comprising the steps of:
a) adding the iodoisocyanate to the 14-15 position double bond on the steroid nucleus; and
b) dehalogenation; and
c) isocyanate conversion to the amine moiety on the 14-position of the steroid nucleus.
本发明涉及通式如下的含寡糖的 14-氨基甾化合物及其药学上可接受的酸盐或酯:
其中
a) R1 是
(i) COOR5,其中
R5 是氢、1-6 碳低烷基、被氨基取代的 1-6 碳低烷基、芳烷基、杂芳烷基或碳环基,或
(ii) CHR6OH,其中
R6 是氢原子或 1-6 碳低烷基,或
(iii) COR''',其中 R'''是氢;1-6 碳低烷基;1-6 碳低烷基取代的氨基;氨基或二烷基氨基;和
b) R2 是-NR7R8,其中
R7 和 R8(可以相同或不同)是氢原子或 1-6 碳低碳烷基;以及
c) R3 是
(i) 具有以下结构的寡糖残基:
其中 R9 是氢;甲基;羟基;羧基;乙酰氧基;芳烷氧基;杂芳烷氧基或苯氧基; R10 是氢;甲基;羧基;乙酰氧基;芳烷氧基;杂芳烷氧基;苯氧基或羟基; R11 是氧;其中,当 R11 是末端单糖糖残基上的取代基时,R11 是 OH;甲基;乙酰氧基;芳基烷氧基;杂芳基烷氧基;以及 R12 是氢;甲基;甲基羟甲基;或乙酰氧甲基;或
(ii) 具有以下结构的寡糖残基:
其中 R14 和 R15(可以相同或不同)是氢;1-6 碳低烷基;杂芳烷基;芳烷基;杂芳基或芳基;R17 可以是氢;羟基;乙酰氧基或苯氧基;R18 和 R19 是羟基;乙酰氧基和苯氧基;或
(iii) 具有以下结构的寡糖残基:
其中 R14 和 R15(可以相同或不同)是氢;1-6 碳低级烷基;杂芳基烷基;芳烷基;杂芳基或芳基;R14a 是氧;其中当 R14a 是末端单糖糖残基上的取代基时,R14a 必须是羟基;甲基;乙酰氧基;芳烷氧基或杂芳基烷氧基;以及
d) R4 是
(i) OH,或
(ii) H,或
(iii) OR13,其中 R13 是单糖糖残基;乙酰氧基;苯氧基;芳烷基或杂芳基;和
e) Z 是
(i) -CH-,其中 a 和 b 为单键,或
(ii) =C,其中 a 或 b 为双键。
本发明还涉及一种在类固醇核的 14 位上引入氨基的工艺,其中所述氨基是通过碘异氰酸酯加成反应,双向选择地引入类固醇核的 14 位上,包括以下步骤:
a) 将碘异氰酸酯加到类固醇核的 14-15 位双键上;以及
b) 脱卤;以及
c) 将异氰酸酯转化为甾体核 14 位上的胺分子。